Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Biotechnology

Healthcare
$119.04 +3.57%

+$3.42 today

Market cap
$8.25B
Beta
1.92
P/E (TTM)
-33.3
EPS (TTM)
-$2.98
52W Low $60.80High $122.20

Volume 2.01M

Average 0.81M

RYTM Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM

Operating Income · Q3 FY2026 · quarter ended Sep 2026

Operating income remains negative

Q3 FY2026 operating income was -$39.27M, compared with -$52.65M a year earlier. Trailing-twelve-month operating income was -$187.25M.

Context

  • Operating income amounted to 101.2% of revenue in FY2025, down 102.8 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 13 analysts of -$338.46M (-76.3%) for the fiscal year ending Dec 2026, a slowdown from the +27.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$39.27M+19.1% QoQ
Last fiscal yearDec 2025
-$192.02M+27.7% YoY
LTMSep 2026
-$187.25M-0.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.4%-307.3%-332.8 pp
1 year+27.7%-76.3%-103.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(192.02M) USD
Year-over-year change
+27.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How RYTM compares with its peers on the latest reported figures

  • RYTM's LTM Sep 2026 operating income of -$187.25M is the 8th highest of the 11 companies compared; the peer median is -$133.31M.
  • Its year-over-year change of -0.6% is the 4th highest of 11, against a peer median of -50.4%.
  • Operating income amounts to 66.7% of revenue for RYTM, versus a peer median of 76.2%.
RYTM Competitors Peer median
Operating Income for RYTM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTNPalatin Technologies, Inc.LTM Mar 2026-$6.52M +72.3%—50.6%
BMEABiomea Fusion, Inc.LTM Mar 2026-$66.57M +49.8%——
SEPNSepterna, Inc.LTM Sep 2026-$73.39M +4.7%—76.2%
BIOABioAge Labs, Inc.LTM Mar 2026-$101.71M -24.3%—985.9%
BLTEBelite Bio, IncLTM Sep 2026-$132.58M -96.2%——
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$134.05M -367.0%—670.3%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$160.33M -76.4%——
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026-$187.25M -0.6%—66.7%
GPCRStructure Therapeutics Inc.LTM Jun 2026-$258.07M -17.5%——
VKTXViking Therapeutics, Inc.LTM Jun 2026-$560.02M -163.1%——
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$81.76B -13383.8%+49.1%8.0%
Peer median (excluding RYTM) -$133.31M-50.4%+49.1%76.2%

Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.15M23.64M77.43M130.13M189.76M
Cost of Revenue599K2.13M9.3M13.37M19.49M
Gross Profit2.56M21.51M68.13M116.76M170.27M
Gross Margin81.0%91.0%88.0%89.7%89.7%
Research & Development104.13M108.63M134.95M237.96M167.34M
Selling, General & Admin68.49M92.03M117.53M144.3M194.94M
Operating Expenses172.61M200.66M252.48M382.26M362.28M
Depreciation & Amortization1.16M1.67M1.76M1.56M1.34M
EBITDA(68.45M)(174.25M)(168.46M)(238.09M)(174.12M)
EBITDA Margin-2170.4%-737.1%-217.6%-183.0%-91.8%
Operating Income(170.06M)(179.16M)(184.36M)(265.5M)(192.02M)
Operating Margin-5391.9%-757.9%-238.1%-204.0%-101.2%
Interest Income447K4.03M13.95M14.71M15.29M
Interest Expense05.2M13.89M20.6M20.58M
Other Income / Expenses100.45M(1.96M)243K5.25M(4.03M)
Income Before Tax(69.61M)(181.12M)(184.11M)(260.26M)(196.04M)
Pre-Tax Margin-2207.1%-766.2%-237.8%-200.0%-103.3%
Income Tax Expense00564K346K497K
Net Income(69.61M)(181.12M)(184.68M)(260.6M)(196.54M)
Net Margin-2207.1%-766.2%-238.5%-200.3%-103.6%
EPS (Basic)(1.37)(3.51)(3.20)(4.34)(3.11)
EPS (Diluted)(1.37)(3.51)(3.20)(4.34)(3.11)
Weighted Avg Shares49.6M52.12M57.67M61M64.98M
Weighted Avg Shares (Diluted)49.6M52.12M57.67M61M64.98M

Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Intrinsic Alpha fair value

Locked

Current Price

$119.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.